Land: Den Europæiske Union
Sprog: engelsk
Kilde: EMA (European Medicines Agency)
bosentan (as monohydrate)
Janssen-Cilag International N.V.
C02KX01
bosentan
Antihypertensives,
Scleroderma, Systemic; Hypertension, Pulmonary
Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in: , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology. , Some improvements have also been shown in patients with PAH WHO functional class II. Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,
Revision: 42
Authorised
2002-05-14
67 B. PACKAGE LEAFLET 68 PACKAGE LEAFLET: INFORMATION FOR THE USER TRACLEER 62.5 MG FILM-COATED TABLETS TRACLEER 125 MG FILM-COATED TABLETS bosentan READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, please ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET 1. What Tracleer is and what it is used for 2. What you need to know before you take Tracleer 3. How to take Tracleer 4. Possible side effects 5. How to store Tracleer 6. Contents of the pack and other information 1. WHAT TRACLEER IS AND WHAT IT IS USED FOR Tracleer tablets contain bosentan, which blocks a naturally occurring hormone called endothelin-1 (ET-1), which causes blood vessels to narrow. Tracleer therefore causes blood vessels to expand and belongs to the class of medicines called “endothelin receptor antagonists”. Tracleer is used to treat: PULMONARY ARTERIAL HYPERTENSION (PAH): PAH is a disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs. This pressure reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult. Tracleer widens the pulmonary arteries, making it easier for the heart to pump blood through them. This lowers the blood pressure and relieves the symptoms. Tracleer is used to treat patients with class III PAH to improve exercise capacity (the ability to carry out physical activity) and symptoms. The ‘class’ reflects the seriousness of the disease: ‘class III’ involves marked limitation of physical Læs hele dokumentet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Tracleer 62.5 mg film-coated tablets Tracleer 125 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tracleer 62.5 mg film-coated tablets Each film-coated tablet contains 62.5 mg bosentan (as monohydrate). Tracleer 125 mg film-coated tablets Each film-coated tablet contains 125 mg bosentan (as monohydrate). Excipient with known effect This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablets): Tracleer 62.5 mg film-coated tablets Orange-white, round, biconvex, film-coated tablets, embossed with “62,5” on one side. Tracleer 125 mg film-coated tablets Orange-white, oval, biconvex, film-coated tablets, embossed with “125” on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in: Primary (idiopathic and heritable) pulmonary arterial hypertension Pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology Some improvements have also been shown in patients with pulmonary arterial hypertension WHO functional class II (see section 5.1). Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease (see section 5.1). 3 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Method of administration Tablets are to be taken orally morning and evening, with or without food. The film-coated tablets are to be swallowed with water. Patients should be advised not to swallow the desiccant found in the white high-density polyethylene bottles. Posology Pulmonary arterial Læs hele dokumentet